{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:29:39Z","timestamp":1783110579810,"version":"3.54.6"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,11]]},"DOI":"10.7759\/cureus.108661","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:29:51Z","timestamp":1778516991000},"source":"Crossref","is-referenced-by-count":1,"title":["Staphylococcus aureus With Reduced Vancomycin Susceptibility: Diagnostic Challenges in Clinical Settings"],"prefix":"10.7759","author":[{"given":"Mithali  B","family":"Jadhav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Karande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1067284","article-title":"MRSA compendium of epidemiology, transmission, pathophysiology, treatment, and prevention within one health framework","volume":"13","author":"Shoaib M","year":"2022","unstructured":"Shoaib M, Aqib AI, Muzammil I, et al.. MRSA compendium of epidemiology, transmission, pathophysiology, treatment, and prevention within one health framework. Front Microbiol. 2022, 13:1067284. 10.3389\/fmicb.2022.1067284","journal-title":"Front Microbiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00020-18","article-title":"Methicillin-resistant Staphylococcus aureus: molecular characterization, evolution, and epidemiology","volume":"31","author":"Lakhundi S","year":"2018","unstructured":"Lakhundi S, Zhang K. Methicillin-resistant Staphylococcus aureus: molecular characterization, evolution, and epidemiology. Clin Microbiol Rev. 2018, 31:e00020-18. 10.1128\/CMR.00020-18","journal-title":"Clin Microbiol Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-018-0147-4","article-title":"Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research","volume":"17","author":"Turner NA","year":"2019","unstructured":"Turner NA, Sharma-Kuinkel BK, Maskarinec SA, et al.. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nat Rev Microbiol. 2019, 17:203-18. 10.1038\/s41579-018-0147-4","journal-title":"Nat Rev Microbiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.1.135","article-title":"Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility","volume":"40","author":"Hiramatsu K","year":"1997","unstructured":"Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997, 40:135-6. 10.1093\/jac\/40.1.135","journal-title":"J Antimicrob Chemother"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2019.10.005","article-title":"Vancomycin resistant Staphylococcus aureus infections: a review of case updating and clinical features","volume":"21","author":"Cong Y","year":"2020","unstructured":"Cong Y, Yang S, Rao X. Vancomycin resistant Staphylococcus aureus infections: a review of case updating and clinical features. J Adv Res. 2020, 21:169-76. 10.1016\/j.jare.2019.10.005","journal-title":"J Adv Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00346-09","article-title":"VanA-type vancomycin-resistant Staphylococcus aureus","volume":"53","author":"P\u00e9richon B","year":"2009","unstructured":"P\u00e9richon B, Courvalin P. VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009, 53:4580-7. 10.1128\/AAC.00346-09","journal-title":"Antimicrob Agents Chemother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1012422","article-title":"Vancomycin-resistant Staphylococcus aureus (VRSA) can overcome the cost of antibiotic resistance and may threaten vancomycin's clinical durability","volume":"20","author":"Blechman SE","year":"2024","unstructured":"Blechman SE, Wright ES. Vancomycin-resistant Staphylococcus aureus (VRSA) can overcome the cost of antibiotic resistance and may threaten vancomycin's clinical durability. PLoS Pathog. 2024, 20:e1012422. 10.1371\/journal.ppat.1012422","journal-title":"PLoS Pathog"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12060972","article-title":"Epidemiology of Staphylococcus aureus non-susceptible to vancomycin in South Asia","volume":"12","author":"Ejaz M","year":"2023","unstructured":"Ejaz M, Syed MA, Jackson CR, Sharif M, Faryal R. Epidemiology of Staphylococcus aureus non-susceptible to vancomycin in South Asia. Antibiotics (Basel). 2023, 12:972. 10.3390\/antibiotics12060972","journal-title":"Antibiotics (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.88122","article-title":"Prevalence and detection of heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) among clinical isolates: a comparative evaluation of screening methods","volume":"17","author":"Agarwal A","year":"2025","unstructured":"Agarwal A, Singhal L, Kour I, Gupta P, Kaur N, Vasesi D, Gupta V. Prevalence and detection of heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) among clinical isolates: a comparative evaluation of screening methods. Cureus. 2025, 17:e88122. 10.7759\/cureus.88122","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas G","year":"2004","unstructured":"Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004, 42:2398-402. 10.1128\/JCM.42.6.2398-2402.2004","journal-title":"J Clin Microbiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5812\/jjm.12831","article-title":"Vancomycin minimum inhibitory concentration for methicillin-resistant Staphylococcus aureus infections; is there difference in mortality between patients?","volume":"7","author":"Aminzadeh Z","year":"2014","unstructured":"Aminzadeh Z, Yadegarynia D, Fatemi A, Tahmasebian Dehkordi E, Azad Armaki S. Vancomycin minimum inhibitory concentration for methicillin-resistant Staphylococcus aureus infections; is there difference in mortality between patients?. Jundishapur J Microbiol. 2014, 7:e12831. 10.5812\/jjm.12831","journal-title":"Jundishapur J Microbiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00239-21","article-title":"Point-counterpoint: should clinical microbiology laboratories report vancomycin MICs?","volume":"59","author":"Revolinski SL","year":"2021","unstructured":"Revolinski SL, Doern CD. Point-counterpoint: should clinical microbiology laboratories report vancomycin MICs?. J Clin Microbiol. 2021, 59:e00239-21. 10.1128\/JCM.00239-21","journal-title":"J Clin Microbiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"Lodise TP","year":"2008","unstructured":"Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008, 52:3315-20. 10.1128\/AAC.00113-08","journal-title":"Antimicrob Agents Chemother"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.18502\/ijph.v52i8.13395","article-title":"Methicillin-resistant Staphylococcus aurous: epidemiology, transmission and new alternative therapies: a narrative review","volume":"52","author":"Bouali N","year":"2023","unstructured":"Bouali N, Haddaji N, Hamadou WS, Ghorbel M, Bechambi O, Mahdhi A, Snoussi M. Methicillin-resistant Staphylococcus aurous: epidemiology, transmission and new alternative therapies: a narrative review. Iran J Public Health. 2023, 52:1555-64. 10.18502\/ijph.v52i8.13395","journal-title":"Iran J Public Health"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00148-22","article-title":"Virulence attributes of successful methicillin-resistant Staphylococcus aureus lineages","volume":"36","author":"Jiang J-H","year":"2023","unstructured":"Jiang J-H, Cameron DR, Nethercott C, Aires-de-Sousa M, Peleg AY. Virulence attributes of successful methicillin-resistant Staphylococcus aureus lineages. Clin Microbiol Rev. 2023, 36:e0014822. 10.1128\/cmr.00148-22","journal-title":"Clin Microbiol Rev"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00775-12","article-title":"Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections","volume":"50","author":"Holmes NE","year":"2012","unstructured":"Holmes NE, Johnson PD, Howden BP. Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections. J Clin Microbiol. 2012, 50:2548-52. 10.1128\/JCM.00775-12","journal-title":"J Clin Microbiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit178","article-title":"Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?","volume":"56","author":"van Hal SJ","year":"2013","unstructured":"van Hal SJ, Fowler VG Jr. Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?. Clin Infect Dis. 2013, 56:1779-88. 10.1093\/cid\/cit178","journal-title":"Clin Infect Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00042-09","article-title":"Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications","volume":"23","author":"Howden BP","year":"2010","unstructured":"Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010, 23:99-139. 10.1128\/CMR.00042-09","journal-title":"Clin Microbiol Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak MJ","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, et al.. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020, 77:835-64. 10.1093\/ajhp\/zxaa036","journal-title":"Am J Health Syst Pharm"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2021.1878688","article-title":"Pathogenicity and virulence of Staphylococcus aureus","volume":"12","author":"Cheung GY","year":"2021","unstructured":"Cheung GY, Bae JS, Otto M. Pathogenicity and virulence of Staphylococcus aureus. Virulence. 2021, 12:547-69. 10.1080\/21505594.2021.1878688","journal-title":"Virulence"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.04317-22","article-title":"Genomic analysis of vancomycin-resistant Staphylococcus aureus isolates from the 3rd case identified in the United States reveals chromosomal integration of the vanA locus","volume":"11","author":"Haas W","year":"2023","unstructured":"Haas W, Singh N, Lainhart W, et al.. Genomic analysis of vancomycin-resistant Staphylococcus aureus isolates from the 3rd case identified in the United States reveals chromosomal integration of the vanA locus. Microbiol Spectr. 2023, 11:e0431722. 10.1128\/spectrum.04317-22","journal-title":"Microbiol Spectr"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S205596","article-title":"Genetic characterization of two vancomycin-resistant Staphylococcus aureus isolates in Kerman, Iran","volume":"12","author":"Ziasistani M","year":"2019","unstructured":"Ziasistani M, Shakibaie MR, Kalantar-Neyestanaki D. Genetic characterization of two vancomycin-resistant Staphylococcus aureus isolates in Kerman, Iran. Infect Drug Resist. 2019, 12:1869-75. 10.2147\/IDR.S205596","journal-title":"Infect Drug Resist"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/lam.13456","article-title":"Cell wall thickness and the molecular mechanism of heterogeneous vancomycin-intermediate Staphylococcus aureus","volume":"72","author":"Cui J","year":"2021","unstructured":"Cui J, Zhang H, Mo Z, Yu M, Liang Z. Cell wall thickness and the molecular mechanism of heterogeneous vancomycin-intermediate Staphylococcus aureus. Lett Appl Microbiol. 2021, 72:604-9. 10.1111\/lam.13456","journal-title":"Lett Appl Microbiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22157927","article-title":"Antimicrobial peptides with antibacterial activity against vancomycin-resistant Staphylococcus aureus strains: classification, structures, and mechanisms of action","volume":"22","author":"Hern\u00e1ndez-Aristiz\u00e1bal I","year":"2021","unstructured":"Hern\u00e1ndez-Aristiz\u00e1bal I, Ocampo-Ib\u00e1\u00f1ez ID. Antimicrobial peptides with antibacterial activity against vancomycin-resistant Staphylococcus aureus strains: classification, structures, and mechanisms of action. Int J Mol Sci. 2021, 22:7927. 10.3390\/ijms22157927","journal-title":"Int J Mol Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-10047-2","article-title":"Reduced vancomycin susceptibility in Staphylococcus aureus clinical isolates: a spectrum of less investigated uncertainties","volume":"24","author":"Tawfeek CE","year":"2024","unstructured":"Tawfeek CE, Khattab S, Elmaraghy N, Heiba AA, Nageeb WM. Reduced vancomycin susceptibility in Staphylococcus aureus clinical isolates: a spectrum of less investigated uncertainties. BMC Infect Dis. 2024, 24:1218. 10.1186\/s12879-024-10047-2","journal-title":"BMC Infect Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02339-z","article-title":"Environmental conditions dictate differential evolution of vancomycin resistance in Staphylococcus aureus","volume":"4","author":"Machado H","year":"2021","unstructured":"Machado H, Seif Y, Sakoulas G, et al.. Environmental conditions dictate differential evolution of vancomycin resistance in Staphylococcus aureus. Commun Biol. 2021, 4:793. 10.1038\/s42003-021-02339-z","journal-title":"Commun Biol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01128-10","article-title":"Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method","volume":"49","author":"Satola SW","year":"2011","unstructured":"Satola SW, Farley MM, Anderson KF, Patel JB. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J Clin Microbiol. 2011, 49:177-83. 10.1128\/JCM.01128-10","journal-title":"J Clin Microbiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S532471","article-title":"Emerging antimicrobial strategies against heterogeneous and vancomycin-intermediate Staphylococcus aureus","volume":"18","author":"Wang Y","year":"2025","unstructured":"Wang Y, Sun Y, Chen G, Cheng X. Emerging antimicrobial strategies against heterogeneous and vancomycin-intermediate Staphylococcus aureus. Int J Gen Med. 2025, 18:5329-44. 10.2147\/IJGM.S532471","journal-title":"Int J Gen Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/484488-staphylococcus-aureus-with-reduced-vancomycin-susceptibility-diagnostic-challenges-in-clinical-settings","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:29:52Z","timestamp":1778516992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/484488-staphylococcus-aureus-with-reduced-vancomycin-susceptibility-diagnostic-challenges-in-clinical-settings"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.108661","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,11]]}}}